Listar por autor "Rondon, C."
Mostrando ítems 1-2 de 2
-
Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
Zubiaga- Fernandez, L.; Testera Montes, Almudena; Rondon, C.; Perez-Sanchez, N.; Gomez- Perez, F.; Vega-Chicote, J. M.; Bartra, Joan; Ferrer, M.; Eguiluz-Gracia, Ibón; Torres-Jaén, María Josefa
[et al.] (Wiley, 2024-02-11)
Background Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher ... -
Organ-specific allergen challenges in airway allergy: Current utilities and future directions
Fauquert, J. L.; Alba-Linero, Carmen; Gherasim, A.; Testera Montes, A.; Bentabol-Ramos, G.; Saenz de Santa María-García, Rocío; Torres-Jaén, María Josefa; Eguiluz-Gracia, Ibón; Rondon, C.[et al.] (Wiley, 2023)
Atopy has been long used as the screening method for airway allergy. Nevertheless, aeroallergens can trigger respiratory symptoms not only in atopic patients (atopic res piratory allergy, ARA), but also in non-atopic ...